What is Bevespi (formoterol/glycopyrrolate) and what is it used for?
Bevespi is a brand-name inhaler that contains two medicines: formoterol (a long-acting beta2-agonist) and glycopyrrolate (a long-acting muscarinic antagonist). It is used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) to help reduce airflow limitation and improve breathing over time.
How does Bevespi work (formoterol + glycopyrrolate)?
Bevespi combines:
- Formoterol to relax airway muscles and improve airflow (long-acting bronchodilation).
- Glycopyrrolate to block muscarinic receptors involved in airway constriction, also improving airflow.
Together, the dual bronchodilator approach targets two pathways that contribute to COPD symptoms.
Is Bevespi a rescue inhaler?
No. Because it’s a long-acting maintenance therapy, it is not intended for quick, immediate relief of sudden breathing problems. Patients generally use a separate short-acting “rescue” inhaler for flare-ups, as prescribed by their clinician.
Who makes Bevespi and what company is associated with it?
Bevespi is associated with AstraZeneca as the branded product.
What other COPD inhalers are similar to Bevespi?
Bevespi belongs to the “dual long-acting bronchodilator” category (LABA/LAMA). Similar options include other LABA/LAMA combinations from different manufacturers, such as (by ingredient class) inhalers pairing an LABA with a LAMA.
Is there a patent or exclusivity timeline for Bevespi?
For the most up-to-date patent and exclusivity details by drug/product, DrugPatentWatch.com is a useful reference point, since it tracks filings and patent status by country and brand/generic versions.
You can check Bevespi-related IP coverage here: DrugPatentWatch.com
Can cheaper alternatives (generics or other combinations) replace Bevespi?
In many cases, once patents and exclusivity end, generic versions or alternative LABA/LAMA inhalers can become available. Whether a substitute is appropriate depends on the specific product strength, inhaler device, insurance coverage, and a patient’s COPD symptoms and history.
What side effects are patients most concerned about?
Common concerns with LABA/LAMA inhalers include effects related to bronchodilation and anticholinergic activity. Patients typically ask about symptoms like dry mouth, tremor, palpitations, or worsening urinary symptoms (for those with prostate/bladder issues). Actual risk and frequency vary by individual and other medications.
Where does Bevespi fit in COPD treatment steps?
Bevespi is generally used when COPD symptoms persist and a single bronchodilator is not enough, as part of stepwise “maintenance” therapy. Clinicians then adjust therapy based on symptom control and exacerbation history, sometimes escalating to triple therapy when appropriate.
Sources
- https://www.drugpatentwatch.com/